OPTHEA LIMITED - Announcements

0.00%

60.0¢

Market Cap $820.7M

Healthcare Biotechnology

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Announcements

Filter Results

All Price Sensitive Only

OPT	S&P DJI Announces September 2025 Quarterly Rebalance	PRICE SENSITIVE	05/09/25	121.47KB	Share
OPT	Application for quotation of securities - OPT		05/09/25	15.75KB	Share
OPT	Preliminary Final Report	PRICE SENSITIVE	29/08/25	325.85KB	Share
OPT	Ceasing to be a substantial holder		22/08/25	304.01KB	Share
OPT	Becoming a substantial holder		21/08/25	843.42KB	Share
OPT	Corporate Update Investor Call	PRICE SENSITIVE	20/08/25	296.94KB	Share
OPT	Application for quotation of securities - OPT		19/08/25	16.61KB	Share
OPT	Opthea Provides Corporate Update	PRICE SENSITIVE	19/08/25	196.61KB	Share
OPT	Application for quotation of securities - OPT		08/08/25	14.6KB	Share
OPT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/25	1.48MB	Share
OPT	Long Term Suspended Entities	PRICE SENSITIVE	16/07/25	262.84KB	Share
OPT	Details of Company Address		04/07/25	287.78KB	Share
OPT	Final Director's Interest Notice Quinton Oswald		02/06/25	862.54KB	Share
OPT	Final Director's Interest Notice Dr Susan Orr		02/06/25	861.92KB	Share
OPT	Final Director's Interest Notice Dr Julia Haller		02/06/25	862.9KB	Share
OPT	Final Director's Interest Notice Anshul Thakral		02/06/25	862.67KB	Share
OPT	Opthea Provides Corporate Update	PRICE SENSITIVE	02/06/25	487.15KB	Share
OPT	Ceasing to be a substantial holder		12/05/25	1.21MB	Share
OPT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	1.48MB	Share
OPT	Opthea Provides Corporate Update	PRICE SENSITIVE	10/04/25	485.05KB	Share
OPT	Continuation of Suspension from Quotation	PRICE SENSITIVE	31/03/25	109.5KB	Share
OPT	Opthea Announces Decision to Discontinue Wet AMD Trials	PRICE SENSITIVE	31/03/25	491.5KB	Share
OPT	Becoming a substantial holder		31/03/25	1003.58KB	Share
OPT	Ceasing to be a substantial holder		25/03/25	742.32KB	Share
OPT	Opthea Announces COAST Phase 3 Trial Topline Results	PRICE SENSITIVE	24/03/25	520.92KB	Share
OPT	Voluntary suspension	PRICE SENSITIVE	19/03/25	1.07MB	Share
OPT	Trading Halt	PRICE SENSITIVE	17/03/25	767.42KB	Share
OPT	Becoming a substantial holder		14/03/25	1.65MB	Share
OPT	Application for quotation of securities - OPT		14/03/25	15.53KB	Share
OPT	Application for quotation of securities - OPT		14/03/25	15.53KB	Share
OPT	Update - Application for quotation of securities - OPT		14/03/25	15.2KB	Share
OPT	Application for quotation of securities - OPT		11/03/25	15.53KB	Share
OPT	Application for quotation of securities - OPT		11/03/25	15.55KB	Share
OPT	Opthea Announces Phase 2b Wet AMD Publication	PRICE SENSITIVE	03/03/25	262.7KB	Share
OPT	Opthea Reports Half Year Results and Business Updates	PRICE SENSITIVE	28/02/25	319.5KB	Share
OPT	Opthea Half Year Financial Report - Appendix 4D	PRICE SENSITIVE	28/02/25	1.25MB	Share
OPT	Opthea Completes Drug Product PPQ Campaign	PRICE SENSITIVE	26/02/25	212.38KB	Share
OPT	Application for quotation of securities - OPT		21/02/25	15.53KB	Share
OPT	Application for quotation of securities - OPT		21/02/25	15.53KB	Share
OPT	Application for quotation of securities - OPT		19/02/25	15.54KB	Share
OPT	Opthea Completes COAST Final Week 52 Patient Visit	PRICE SENSITIVE	18/02/25	190.33KB	Share
OPT	Application for quotation of securities - OPT		17/02/25	15.54KB	Share
OPT	Notification of cessation of securities - OPT		11/02/25	12.85KB	Share
OPT	Application for quotation of securities - OPT		11/02/25	15.54KB	Share
OPT	Opthea to Present at Oppenheimer Healthcare Conference		07/02/25	160.87KB	Share
OPT	Opthea Wet AMD Data Featured at Macula Society Meeting		06/02/25	187.97KB	Share
OPT	Change in substantial holding		04/02/25	94.94KB	Share
OPT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/25	1.49MB	Share
OPT	Application for quotation of securities - OPT		30/01/25	15.53KB	Share
OPT	Opthea Investor Day	PRICE SENSITIVE	29/01/25	2.98MB	Share
OPT	Opthea's Corporate Presentation - Jan 2025	PRICE SENSITIVE	14/01/25	1.77MB	Share
OPT	Opthea to Host Investor Days in New York and Australia		08/01/25	173.24KB	Share
OPT	Opthea Announces Publication in Diabetic Macular Edema	PRICE SENSITIVE	07/01/25	520.96KB	Share
OPT	Application for quotation of securities - OPT		24/12/24	16.12KB	Share
OPT	Notification regarding unquoted securities - OPT		24/12/24	15.74KB	Share
OPT	Notification of cessation of securities - OPT		24/12/24	12.85KB	Share
OPT	Notification regarding unquoted securities - OPT		24/12/24	15.74KB	Share
OPT	Opthea to Present at 43rd J.P. Morgan Healthcare Conference		19/12/24	273.99KB	Share
OPT	Change of Director's Interest Notice - SS		17/12/24	1020.49KB	Share
OPT	Change of Director's Interest Notice - SO		17/12/24	1020.48KB	Share
OPT	Change of Director's Interest Notice - QO		17/12/24	1020.94KB	Share
OPT	Change of Director's Interest Notice - LG		17/12/24	839.63KB	Share
OPT	Change of Director's Interest Notice - JH		17/12/24	1022KB	Share
OPT	Change of Director's Interest Notice -AT		17/12/24	1021.52KB	Share
OPT	Change of Director's Interest Notice - JL		17/12/24	1022.6KB	Share
OPT	Notification regarding unquoted securities - OPT		16/12/24	16.06KB	Share
OPT	Notification regarding unquoted securities - OPT		16/12/24	16.13KB	Share
OPT	Notification regarding unquoted securities - OPT		16/12/24	16.53KB	Share
OPT	Notification regarding unquoted securities - OPT		16/12/24	17.71KB	Share
OPT	Opthea's Wet AMD Program to be Featured at FLORetina 2024	PRICE SENSITIVE	26/11/24	378.43KB	Share
OPT	Opthea Participate in Citi 2024 Global Healthcare Conference		25/11/24	200.6KB	Share
OPT	Initial Director's Interest Notice		15/11/24	786.71KB	Share
OPT	Opthea Received A$15.9 Million R&D Tax Incentive	PRICE SENSITIVE	15/11/24	217.04KB	Share
OPT	Results of Meeting		15/11/24	342.98KB	Share
OPT	Director Appointment/Resignation		15/11/24	463.08KB	Share
OPT	Chair's Address to Shareholders	PRICE SENSITIVE	15/11/24	234.64KB	Share
OPT	Opthea's Wet AMD Program Featured at Ophthalmology Events		12/11/24	457.02KB	Share
OPT	Update Opthea Participates in November Investor Conferences		04/11/24	445.94KB	Share
OPT	Opthea to Participate in November Investor Conferences		04/11/24	445.46KB	Share
OPT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	1.42MB	Share
OPT	Opthea Corporate Presentation - Oct 2024	PRICE SENSITIVE	28/10/24	1.21MB	Share
OPT	Notice of Annual General Meeting/Proxy Form		16/10/24	1.02MB	Share
OPT	Opthea Files Notice of Annual General Meeting		16/10/24	457.86KB	Share
OPT	Opthea Wet AMD Program to be Presented at Innovate Retina		10/10/24	378.83KB	Share
OPT	Opthea Appoints Chief Medical and Chief Financial Officer		08/10/24	464.99KB	Share
OPT	Becoming a substantial holder		04/10/24	272.58KB	Share
OPT	Opthea to participate in UBS Virtual Ophthalmology Day 2024		01/10/24	429.36KB	Share
OPT	Opthea EURetina Symposium 2024	PRICE SENSITIVE	26/09/24	1.71MB	Share
OPT	Opthea Joins the S&P/ASX 300 Index	PRICE SENSITIVE	23/09/24	269.22KB	Share
OPT	Opthea Announces Completion of Drug Substance Campaign	PRICE SENSITIVE	19/09/24	460.69KB	Share
OPT	Opthea Presents at the 24th EURETINA Congress		11/09/24	650.16KB	Share
OPT	Opthea Corporate Presentation - September 2024	PRICE SENSITIVE	09/09/24	1.41MB	Share
OPT	S&P DJI Announces September 2024 Quarterly Rebalance	PRICE SENSITIVE	06/09/24	145.4KB	Share
OPT	Opthea Announces Executive Leadership Changes & Senior Hires		05/09/24	536.23KB	Share
OPT	Opthea presents at H.C.Wainwright 26th Investment Conference		04/09/24	121.97KB	Share
OPT	Opthea 2024 Corporate Governance Statement		30/08/24	1.08MB	Share
OPT	Opthea Reports Full-Year Results	PRICE SENSITIVE	30/08/24	904.23KB	Share
OPT	Opthea Preliminary Final and Annual Report	PRICE SENSITIVE	30/08/24	4.63MB	Share
OPT	Opthea to Participate in H.C Wainwright Virtual Conference		09/08/24	433.73KB	Share
OPT	Updated Quarterly Report and Cashflow	PRICE SENSITIVE	01/08/24	2.18MB	Share

OPT S&P DJI Announces September 2025 Quarterly Rebalance
05/09/25	PRICE SENSITIVE	121.47KB	Share
OPT Application for quotation of securities - OPT
05/09/25		15.75KB	Share
OPT Preliminary Final Report
29/08/25	PRICE SENSITIVE	325.85KB	Share
OPT Ceasing to be a substantial holder
22/08/25		304.01KB	Share
OPT Becoming a substantial holder
21/08/25		843.42KB	Share
OPT Corporate Update Investor Call
20/08/25	PRICE SENSITIVE	296.94KB	Share
OPT Application for quotation of securities - OPT
19/08/25		16.61KB	Share
OPT Opthea Provides Corporate Update
19/08/25	PRICE SENSITIVE	196.61KB	Share
OPT Application for quotation of securities - OPT
08/08/25		14.6KB	Share
OPT Quarterly Activities/Appendix 4C Cash Flow Report
30/07/25	PRICE SENSITIVE	1.48MB	Share
OPT Long Term Suspended Entities
16/07/25	PRICE SENSITIVE	262.84KB	Share
OPT Details of Company Address
04/07/25		287.78KB	Share
OPT Final Director's Interest Notice Quinton Oswald
02/06/25		862.54KB	Share
OPT Final Director's Interest Notice Dr Susan Orr
02/06/25		861.92KB	Share
OPT Final Director's Interest Notice Dr Julia Haller
02/06/25		862.9KB	Share
OPT Final Director's Interest Notice Anshul Thakral
02/06/25		862.67KB	Share
OPT Opthea Provides Corporate Update
02/06/25	PRICE SENSITIVE	487.15KB	Share
OPT Ceasing to be a substantial holder
12/05/25		1.21MB	Share
OPT Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	1.48MB	Share
OPT Opthea Provides Corporate Update
10/04/25	PRICE SENSITIVE	485.05KB	Share
OPT Continuation of Suspension from Quotation
31/03/25	PRICE SENSITIVE	109.5KB	Share
OPT Opthea Announces Decision to Discontinue Wet AMD Trials
31/03/25	PRICE SENSITIVE	491.5KB	Share
OPT Becoming a substantial holder
31/03/25		1003.58KB	Share
OPT Ceasing to be a substantial holder
25/03/25		742.32KB	Share
OPT Opthea Announces COAST Phase 3 Trial Topline Results
24/03/25	PRICE SENSITIVE	520.92KB	Share
OPT Voluntary suspension
19/03/25	PRICE SENSITIVE	1.07MB	Share
OPT Trading Halt
17/03/25	PRICE SENSITIVE	767.42KB	Share
OPT Becoming a substantial holder
14/03/25		1.65MB	Share
OPT Application for quotation of securities - OPT
14/03/25		15.53KB	Share
OPT Application for quotation of securities - OPT
14/03/25		15.53KB	Share
OPT Update - Application for quotation of securities - OPT
14/03/25		15.2KB	Share
OPT Application for quotation of securities - OPT
11/03/25		15.53KB	Share
OPT Application for quotation of securities - OPT
11/03/25		15.55KB	Share
OPT Opthea Announces Phase 2b Wet AMD Publication
03/03/25	PRICE SENSITIVE	262.7KB	Share
OPT Opthea Reports Half Year Results and Business Updates
28/02/25	PRICE SENSITIVE	319.5KB	Share
OPT Opthea Half Year Financial Report - Appendix 4D
28/02/25	PRICE SENSITIVE	1.25MB	Share
OPT Opthea Completes Drug Product PPQ Campaign
26/02/25	PRICE SENSITIVE	212.38KB	Share
OPT Application for quotation of securities - OPT
21/02/25		15.53KB	Share
OPT Application for quotation of securities - OPT
21/02/25		15.53KB	Share
OPT Application for quotation of securities - OPT
19/02/25		15.54KB	Share
OPT Opthea Completes COAST Final Week 52 Patient Visit
18/02/25	PRICE SENSITIVE	190.33KB	Share
OPT Application for quotation of securities - OPT
17/02/25		15.54KB	Share
OPT Notification of cessation of securities - OPT
11/02/25		12.85KB	Share
OPT Application for quotation of securities - OPT
11/02/25		15.54KB	Share
OPT Opthea to Present at Oppenheimer Healthcare Conference
07/02/25		160.87KB	Share
OPT Opthea Wet AMD Data Featured at Macula Society Meeting
06/02/25		187.97KB	Share
OPT Change in substantial holding
04/02/25		94.94KB	Share
OPT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/25	PRICE SENSITIVE	1.49MB	Share
OPT Application for quotation of securities - OPT
30/01/25		15.53KB	Share
OPT Opthea Investor Day
29/01/25	PRICE SENSITIVE	2.98MB	Share
OPT Opthea's Corporate Presentation - Jan 2025
14/01/25	PRICE SENSITIVE	1.77MB	Share
OPT Opthea to Host Investor Days in New York and Australia
08/01/25		173.24KB	Share
OPT Opthea Announces Publication in Diabetic Macular Edema
07/01/25	PRICE SENSITIVE	520.96KB	Share
OPT Application for quotation of securities - OPT
24/12/24		16.12KB	Share
OPT Notification regarding unquoted securities - OPT
24/12/24		15.74KB	Share
OPT Notification of cessation of securities - OPT
24/12/24		12.85KB	Share
OPT Notification regarding unquoted securities - OPT
24/12/24		15.74KB	Share
OPT Opthea to Present at 43rd J.P. Morgan Healthcare Conference
19/12/24		273.99KB	Share
OPT Change of Director's Interest Notice - SS
17/12/24		1020.49KB	Share
OPT Change of Director's Interest Notice - SO
17/12/24		1020.48KB	Share
OPT Change of Director's Interest Notice - QO
17/12/24		1020.94KB	Share
OPT Change of Director's Interest Notice - LG
17/12/24		839.63KB	Share
OPT Change of Director's Interest Notice - JH
17/12/24		1022KB	Share
OPT Change of Director's Interest Notice -AT
17/12/24		1021.52KB	Share
OPT Change of Director's Interest Notice - JL
17/12/24		1022.6KB	Share
OPT Notification regarding unquoted securities - OPT
16/12/24		16.06KB	Share
OPT Notification regarding unquoted securities - OPT
16/12/24		16.13KB	Share
OPT Notification regarding unquoted securities - OPT
16/12/24		16.53KB	Share
OPT Notification regarding unquoted securities - OPT
16/12/24		17.71KB	Share
OPT Opthea's Wet AMD Program to be Featured at FLORetina 2024
26/11/24	PRICE SENSITIVE	378.43KB	Share
OPT Opthea Participate in Citi 2024 Global Healthcare Conference
25/11/24		200.6KB	Share
OPT Initial Director's Interest Notice
15/11/24		786.71KB	Share
OPT Opthea Received A$15.9 Million R&D Tax Incentive
15/11/24	PRICE SENSITIVE	217.04KB	Share
OPT Results of Meeting
15/11/24		342.98KB	Share
OPT Director Appointment/Resignation
15/11/24		463.08KB	Share
OPT Chair's Address to Shareholders
15/11/24	PRICE SENSITIVE	234.64KB	Share
OPT Opthea's Wet AMD Program Featured at Ophthalmology Events
12/11/24		457.02KB	Share
OPT Update Opthea Participates in November Investor Conferences
04/11/24		445.94KB	Share
OPT Opthea to Participate in November Investor Conferences
04/11/24		445.46KB	Share
OPT Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	1.42MB	Share
OPT Opthea Corporate Presentation - Oct 2024
28/10/24	PRICE SENSITIVE	1.21MB	Share
OPT Notice of Annual General Meeting/Proxy Form
16/10/24		1.02MB	Share
OPT Opthea Files Notice of Annual General Meeting
16/10/24		457.86KB	Share
OPT Opthea Wet AMD Program to be Presented at Innovate Retina
10/10/24		378.83KB	Share
OPT Opthea Appoints Chief Medical and Chief Financial Officer
08/10/24		464.99KB	Share
OPT Becoming a substantial holder
04/10/24		272.58KB	Share
OPT Opthea to participate in UBS Virtual Ophthalmology Day 2024
01/10/24		429.36KB	Share
OPT Opthea EURetina Symposium 2024
26/09/24	PRICE SENSITIVE	1.71MB	Share
OPT Opthea Joins the S&P/ASX 300 Index
23/09/24	PRICE SENSITIVE	269.22KB	Share
OPT Opthea Announces Completion of Drug Substance Campaign
19/09/24	PRICE SENSITIVE	460.69KB	Share
OPT Opthea Presents at the 24th EURETINA Congress
11/09/24		650.16KB	Share
OPT Opthea Corporate Presentation - September 2024
09/09/24	PRICE SENSITIVE	1.41MB	Share
OPT S&P DJI Announces September 2024 Quarterly Rebalance
06/09/24	PRICE SENSITIVE	145.4KB	Share
OPT Opthea Announces Executive Leadership Changes & Senior Hires
05/09/24		536.23KB	Share
OPT Opthea presents at H.C.Wainwright 26th Investment Conference
04/09/24		121.97KB	Share
OPT Opthea 2024 Corporate Governance Statement
30/08/24		1.08MB	Share
OPT Opthea Reports Full-Year Results
30/08/24	PRICE SENSITIVE	904.23KB	Share
OPT Opthea Preliminary Final and Annual Report
30/08/24	PRICE SENSITIVE	4.63MB	Share
OPT Opthea to Participate in H.C Wainwright Virtual Conference
09/08/24		433.73KB	Share
OPT Updated Quarterly Report and Cashflow
01/08/24	PRICE SENSITIVE	2.18MB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 60.0¢		Change 0.000(0.00%)		Mkt cap ! $820.7M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

OPT (ASX) Chart

Day chart unavailable

OPTHEA LIMITED - Announcements

Announcements

Top Stories